Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
about
Detection of minimal residual disease: methods and relationship to outcome in T-lineage acute lymphoblastic leukemia.Detection of residual disease in acute lymphoblastic leukemia of childhood.Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease.Clonal diversity of Ig and T-cell receptor gene rearrangements in childhood B-precursor acute lymphoblastic leukaemia.Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation.Biology and treatment of adult acute lymphoblastic leukemiaA set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALLImmunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingEarly response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review.Survival of B lineage leukemic cells: signals from the bone marrow microenvironment.Biologically-generated primer for PCR: PCR primer of unknown sequenceBone marrow transfusions in cadaver renal allografts: pilot trials with concurrent controls.Noninvasive identification of subcellular organization and nuclear morphology features associated with leukemic cells using light-scattering spectroscopyDevelopment and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma.Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Measurements of treatment response in childhood acute leukemia.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.Progress of minimal residual disease studies in childhood acute leukemia.Minimal residual disease in acute lymphoblastic leukemiaDetermining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.Status of minimal residual disease testing in childhood haematological malignanciesRole of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapseShould minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript.Advances and issues in flow cytometric detection of immunophenotypic changes and genomic rearrangements in acute pediatric leukemia.Digital PCR: A brief history.The molecular detection of circulating tumour cellsClinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure?The clinical value of detecting gene rearrangements in acute leukaemias.Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia.Prognostic significance of bi/oligoclonality in childhood acute lymphoblastic leukemia as determined by polymerase chain reaction.The study of minimal residual disease in acute lymphoblastic leukaemia.
P2860
Q33536289-6613DE55-4792-47AD-AB5A-4AA7FDA15292Q33588820-E8E35C99-821D-4F4C-8FF1-E277DA912258Q33656184-350C519C-C5F6-465F-B6D8-4DB86A73A8BCQ33723609-FB4EC41F-003E-4884-B9CA-69B15F7CBB0AQ33837936-D24FB090-EA04-4458-AC6E-EAC8FB5347FAQ33929829-234B2D20-6CE4-4322-B105-5F451D5B6C50Q34135330-42706612-46BA-4CD0-B752-8F63192BE4D6Q34182822-45B40E9E-D582-460E-BCA1-3B7DEA40CB5FQ34217173-54B78693-5A63-456C-8A99-0A53B76318FCQ34425875-33FAF63E-F3CE-44A0-9F64-5A2641DC9666Q34448334-69934094-433E-4AFA-8DAE-232941823D8DQ34573970-48E13505-7886-446A-938B-7301444343D2Q34669686-E75AD19C-3C8F-4065-8EAD-52B116B15FD8Q34842525-71642767-7686-4B54-8180-2F06A56C4CB3Q34849823-83D1D8D7-23C7-4C14-9CB2-C956F3E0C5C2Q35786822-3FCEEF93-72C5-4380-BEAB-E4C89716782FQ35853569-E04EAB71-D5C5-4D87-A5D0-67DB924710BCQ35989461-0FCBAC1F-B250-440F-B1B3-E65467BCB0A0Q36366977-8F826E87-E006-466D-BC95-665C40107967Q36513773-3A503528-0A80-454C-B27D-398194CAA895Q36731636-72FEF317-CD2C-432A-BF91-D3E35736ABD9Q36960646-F66F0747-5823-4B67-9748-4230D92F937EQ36981845-B74A484E-C536-43BB-8669-797DE2E0937FQ37077352-547EA920-6D20-4450-9AC4-9F085A859F91Q37164456-4AF1015A-4831-43D9-BF8C-E0233F550AF4Q37164460-60E187A1-CFBC-4D1A-9022-5B9D7025A596Q37246360-BD725474-2079-4F6A-B182-CA7EF82508C8Q37389544-028BB326-233C-443F-B33A-49E13500F0BDQ37641515-C41EDE4D-310F-49CF-9CAB-C68EE389F06EQ37989006-805D3629-5672-4B9B-996A-B19B618A7C2CQ38113738-90FE0923-15A3-4DC6-8AE9-EB9D9E6FBC74Q38319141-93360ABA-91E9-4079-926E-F79711B485DCQ38719359-0D22F7C4-B454-45C0-98B5-822BFB55C9F1Q39030238-A6858D26-2D81-4591-B81E-32B59F7D9889Q40462686-2C461481-8CDD-4D28-931F-9580D9EB9EDEQ40493980-2DAA5A33-1E60-41C0-9E0A-B707EB331E08Q40567857-F0DCF731-FCFE-4B52-8DD5-F8204419E3D1Q40621159-46097A30-C237-4DD0-B200-7DAAD2495876Q40766466-ACF0BBF2-BEEA-438E-9FD6-CED7B4EC95D2Q40848677-9C617530-FB75-4B5F-B48A-63C712C113D1
P2860
Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
name
Outcome prediction in childhoo ...... sease at the end of induction.
@ast
Outcome prediction in childhoo ...... sease at the end of induction.
@en
Outcome prediction in childhoo ...... sease at the end of induction.
@nl
type
label
Outcome prediction in childhoo ...... sease at the end of induction.
@ast
Outcome prediction in childhoo ...... sease at the end of induction.
@en
Outcome prediction in childhoo ...... sease at the end of induction.
@nl
prefLabel
Outcome prediction in childhoo ...... sease at the end of induction.
@ast
Outcome prediction in childhoo ...... sease at the end of induction.
@en
Outcome prediction in childhoo ...... sease at the end of induction.
@nl
P2093
P1433
P1476
Outcome prediction in childhoo ...... sease at the end of induction.
@en
P2093
M J Brisco
R Seshadri
P304
P356
10.1016/S0140-6736(94)90988-1
P407
P577
1994-01-01T00:00:00Z